TCR2 THERAPEUTICS INC's ticker is TCRR and the CUSIP is 87808K106. A total of 121 filers reported holding TCR2 THERAPEUTICS INC in Q4 2020. The put-call ratio across all filers is 1.04 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q1 2023 | $667 | -3.6% | 444,800 | -35.8% | 0.00% | 0.0% |
| Q4 2022 | $692 | -99.9% | 693,286 | -1.9% | 0.00% | -50.0% |
| Q3 2022 | $1,272,000 | -41.6% | 706,900 | -5.9% | 0.00% | -33.3% |
| Q2 2022 | $2,179,000 | -45.3% | 751,300 | -47.9% | 0.00% | -40.0% |
| Q1 2022 | $3,982,000 | -4.2% | 1,442,600 | +61.7% | 0.01% | 0.0% |
| Q4 2021 | $4,156,000 | +152.0% | 891,900 | +360.2% | 0.01% | +150.0% |
| Q3 2021 | $1,649,000 | -37.8% | 193,800 | +20.1% | 0.00% | -33.3% |
| Q2 2021 | $2,649,000 | -19.2% | 161,400 | +8.7% | 0.00% | -25.0% |
| Q1 2021 | $3,279,000 | +138.3% | 148,500 | +119.4% | 0.00% | +300.0% |
| Q3 2020 | $1,376,000 | +162.6% | 67,700 | +98.5% | 0.00% | – |
| Q2 2020 | $524,000 | +32.0% | 34,100 | -33.5% | 0.00% | – |
| Q1 2020 | $397,000 | – | 51,300 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| MPM BioImpact LLC | 6,741,964 | $208,528,000 | 18.01% |
| MPM ASSET MANAGEMENT LLC | 4,050,865 | $125,293,000 | 17.73% |
| Consonance Capital Management LP | 584,885 | $71,268,000 | 6.66% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 136,000 | $4,206,000 | 2.44% |
| Redmile Group, LLC | 2,832,888 | $87,621,000 | 1.06% |
| Altium Capital Management LP | 73,991 | $2,289,000 | 0.86% |
| PFM Health Sciences, LP | 775,794 | $23,995,000 | 0.84% |
| Soleus Capital Management, L.P. | 199,867 | $6,182,000 | 0.82% |
| MOODY ALDRICH PARTNERS LLC | 123,639 | $3,824,000 | 0.62% |
| Sofinnova Investments, Inc. | 333,707 | $10,322,000 | 0.61% |